X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs SUN PHARMA - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD SUN PHARMA ALEMBIC LTD/
SUN PHARMA
 
P/E (TTM) x 50.2 41.9 119.7% View Chart
P/BV x 2.1 3.3 66.1% View Chart
Dividend Yield % 0.5 0.4 122.2%  

Financials

 ALEMBIC LTD   SUN PHARMA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
SUN PHARMA
Mar-18
ALEMBIC LTD/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs72701 10.3%   
Low Rs34433 7.8%   
Sales per share (Unadj.) Rs4.7110.4 4.3%  
Earnings per share (Unadj.) Rs6.111.0 55.6%  
Cash flow per share (Unadj.) Rs6.217.2 36.2%  
Dividends per share (Unadj.) Rs0.202.00 10.0%  
Dividend yield (eoy) %0.40.4 107.1%  
Book value per share (Unadj.) Rs40.7158.8 25.6%  
Shares outstanding (eoy) m267.032,399.26 11.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.35.1 219.4%   
Avg P/E ratio x8.751.6 16.8%  
P/CF ratio (eoy) x8.532.9 25.8%  
Price / Book Value ratio x1.33.6 36.5%  
Dividend payout %3.318.2 18.0%   
Avg Mkt Cap Rs m14,1391,360,021 1.0%   
No. of employees `000NA17.8 0.0%   
Total wages/salary Rs m20753,671 0.4%   
Avg. sales/employee Rs ThNM14,890.9-  
Avg. wages/employee Rs ThNM3,017.1-  
Avg. net profit/employee Rs ThNM1,480.6-  
INCOME DATA
Net Sales Rs m1,255264,895 0.5%  
Other income Rs m3708,388 4.4%   
Total revenues Rs m1,625273,282 0.6%   
Gross profit Rs m11156,081 0.2%  
Depreciation Rs m3814,998 0.3%   
Interest Rs m25,176 0.0%   
Profit before tax Rs m44244,295 1.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m248,452 0.3%   
Profit after tax Rs m1,63026,338 6.2%  
Gross profit margin %8.921.2 41.8%  
Effective tax rate %5.419.1 28.4%   
Net profit margin %129.89.9 1,306.0%  
BALANCE SHEET DATA
Current assets Rs m1,867316,359 0.6%   
Current liabilities Rs m591198,643 0.3%   
Net working cap to sales %101.644.4 228.7%  
Current ratio x3.21.6 198.3%  
Inventory Days Days9495 99.4%  
Debtors Days Days74108 68.3%  
Net fixed assets Rs m1,791213,178 0.8%   
Share capital Rs m5342,399 22.3%   
"Free" reserves Rs m10,324378,606 2.7%   
Net worth Rs m10,858381,006 2.8%   
Long term debt Rs m4117,721 0.2%   
Total assets Rs m11,591643,028 1.8%  
Interest coverage x260.99.6 2,729.4%   
Debt to equity ratio x00 8.2%  
Sales to assets ratio x0.10.4 26.3%   
Return on assets %14.14.9 287.2%  
Return on equity %15.06.9 217.2%  
Return on capital %15.210.0 151.5%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1940,816 0.0%   
Fx outflow Rs m26430,143 0.9%   
Net fx Rs m-24410,673 -2.3%   
CASH FLOW
From Operations Rs m23639,072 0.6%  
From Investments Rs m-224-33,708 0.7%  
From Financial Activity Rs m-27-15,393 0.2%  
Net Cashflow Rs m-15-7,359 0.2%  

Share Holding

Indian Promoters % 64.0 63.7 100.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 5.1 3.9%  
FIIs % 9.7 23.0 42.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 8.3 314.5%  
Shareholders   54,701 133,026 41.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   ALKEM LABORATORIES  PLETHICO PHARMA  WOCKHARDT LTD.  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare ALEMBIC LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views on News

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (2QFY19); Net Profit Up 4.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Nov 15, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 8-QTR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS